- Home
- IMTX vs NNNN Comparison
IMTX vs NNNN Comparison
Compare IMTX & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | NNNN |
|---|---|---|
| Founded | N/A | 2021 |
| Country | Germany | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | IMTX | NNNN |
|---|---|---|
| Price | $10.18 | $37.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $19.25 | N/A |
| AVG Volume (30 Days) | ★ 657.4K | 25.7K |
| Earning Date | 11-17-2025 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $99,445,031.00 | $8,185,146.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.39 | N/A |
| P/E Ratio | ★ N/A | $684.40 |
| Revenue Growth | N/A | ★ 21.95 |
| 52 Week Low | $3.30 | $5.18 |
| 52 Week High | $12.41 | $55.65 |
Technical Indicators
Market Signals| Indicator | IMTX | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 67.42 |
| Support Level | $9.76 | $21.13 |
| Resistance Level | $12.41 | $29.38 |
| Average True Range (ATR) | 0.87 | 4.90 |
| MACD | 0.01 | 2.01 |
| Stochastic Oscillator | 36.85 | 75.29 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.